|1.||Yamamoto, Satoshi: 3 articles (03/2007 - 07/2006)|
|2.||Shimizu, Yasuaki: 3 articles (03/2007 - 07/2006)|
|3.||Ikeda, Ken: 3 articles (03/2007 - 07/2006)|
|4.||Sugahara, Shingo: 3 articles (03/2007 - 07/2006)|
|5.||Ichikawa, Atsushi: 1 article (07/2006)|
|6.||Yamada, Toshimitsu: 1 article (07/2006)|
|7.||Naito, Ryo: 1 article (07/2006)|
03/22/2007 - "In this study, we investigated the therapeutic potential of YM-393059 for the treatment of rheumatoid arthritis in several animal models. "
03/22/2007 - "These results suggest that YM-393059 is an attractive compound for the treatment of autoimmune disorders such as rheumatoid arthritis."
11/21/2006 - "To characterize the pharmacological profile of YM-393059, its effects on several acute and chronic inflammation models were examined. "
11/21/2006 - "Pharmacological profile of a novel phosphodiesterase 7A and -4 dual inhibitor, YM-393059, on acute and chronic inflammation models."
11/21/2006 - "In acute inflammation models, YM-393059 significantly suppressed the delayed-type hypersensitivity reaction to sheep red blood cells in mice with an ED(50) value of 17.1 mg/kg. YM-393059 failed to suppress paw edema in the carrageenin-induced edema model in rats. "
11/21/2006 - "However, YM-393059, but not cyclosporine, significantly inhibited zymosan-induced neutrophil accumulation in mice with an ED(50) value of 25.7 mg/kg. In mouse toluene-2,4-diisocyanate-induced contact dermatitis, a chronic inflammation model, YM-393059 and cyclosporine significantly suppressed ear edema at doses of 30 and 20 mg/kg, respectively. "
|2.||Phosphodiesterase 4 Inhibitors
|3.||Type 7 Cyclic Nucleotide Phosphodiesterases